Key Takeaways
- • EQT Private Equity agreed to a takeover offer for Qiagen valued at 10.8 billion euros (about $12.1 billion), including approximately $1.1 billion of debt, according to Qiagen's announcement.
- • The all-cash offer of 46.50 euros per share (about $52.20) represents a premium of roughly 40% to Qiagen's July 8 Xetra closing price of 33.15 euros, the last trading day before private equity takeover interest was reported.
- • Qiagen's supervisory and managing boards, after reviewing strategic options with both strategic and financial parties, agreed to recommend the offer and fully support the transaction.
- • William Blair analysts called the price reasonable, noting it implies about 15 times their 2027 EBITDA estimate, below the high-teens to low-20s multiples typical of comparable life sciences deals.
- • The deal is expected to close in mid-2027, subject to Qiagen shareholder and regulatory approvals, and Qiagen will continue to operate under its name.
Summary
Qiagen said on Wednesday that it has agreed to a takeover offer from EQT Private Equity valued at 10.8 billion euros (about $12.1 billion), including approximately $1.1 billion of debt. The diagnostics company has long been a rumored takeover target, and the agreement comes less than two months after it installed Jonathan Pratt as chief executive. Six years ago, Thermo Fisher Scientific agreed to buy Qiagen, but that transaction collapsed after shareholders objected to the price.
The all-cash offer of 46.50 euros per share (about $52.20) represents a premium of roughly 40% to Qiagen's closing share price of 33.15 euros on the Xetra electronic trading system on July 8, the last trading day before reports of private equity takeover interest were published, according to Qiagen. Qiagen's supervisory and managing boards, following a review of strategic options that included discussions with both strategic and financial parties, agreed to recommend accepting the offer and fully support the transaction.
Pratt said that under private ownership the company can move faster and has greater freedom to direct resources toward the opportunities that best align with its long-term strategy. Qiagen said the structure will give it more flexibility to invest for the long term and better position it to deliver on its full potential. EQT has committed to support Qiagen's long-term development, including commitments related to strategy, business, key brands, operational footprint, R&D activities, employee arrangements and financing, and Qiagen will continue to operate under its name.
William Blair analysts, in a Thursday note, said the all-cash price was reasonable given Qiagen's relatively lower growth profile. The deal price implies about 15 times William Blair's estimate for 2027 earnings before interest, tax, depreciation and amortization, below the high-teens to low-20s multiples the analysts said are typical of comparable life sciences transactions. They added that "there is plenty to like about Qiagen's core portfolio," but that "broader-based growth has remained elusive, with gains in some businesses offset by headwinds elsewhere."
The transaction is expected to close in mid-2027, subject to approvals from Qiagen shareholders and regulators.
The all-cash offer of 46.50 euros per share (about $52.20) represents a premium of roughly 40% to Qiagen's closing share price of 33.15 euros on the Xetra electronic trading system on July 8, the last trading day before reports of private equity takeover interest were published, according to Qiagen. Qiagen's supervisory and managing boards, following a review of strategic options that included discussions with both strategic and financial parties, agreed to recommend accepting the offer and fully support the transaction.
Pratt said that under private ownership the company can move faster and has greater freedom to direct resources toward the opportunities that best align with its long-term strategy. Qiagen said the structure will give it more flexibility to invest for the long term and better position it to deliver on its full potential. EQT has committed to support Qiagen's long-term development, including commitments related to strategy, business, key brands, operational footprint, R&D activities, employee arrangements and financing, and Qiagen will continue to operate under its name.
William Blair analysts, in a Thursday note, said the all-cash price was reasonable given Qiagen's relatively lower growth profile. The deal price implies about 15 times William Blair's estimate for 2027 earnings before interest, tax, depreciation and amortization, below the high-teens to low-20s multiples the analysts said are typical of comparable life sciences transactions. They added that "there is plenty to like about Qiagen's core portfolio," but that "broader-based growth has remained elusive, with gains in some businesses offset by headwinds elsewhere."
The transaction is expected to close in mid-2027, subject to approvals from Qiagen shareholders and regulators.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.